Katie Tryhane
Stock Analyst at Credit Suisse
(1.98)
# 2,902
Out of 4,711 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $185.77 | +53.42% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $21.21 | +135.74% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $228.55 | +61.89% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.26 | +574.85% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $412.26 | +86.78% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $5.37 | +905.59% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $18.34 | +254.42% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $164.84 | +39.53% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $18.70 | +194.12% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $89.29 | -77.60% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $524.05 | -6.50% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $211.06 | +144.01% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $207.51 | +13.25% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $185.77
Upside: +53.42%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $21.21
Upside: +135.74%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $228.55
Upside: +61.89%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.26
Upside: +574.85%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $412.26
Upside: +86.78%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $5.37
Upside: +905.59%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $18.34
Upside: +254.42%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $164.84
Upside: +39.53%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $18.70
Upside: +194.12%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $89.29
Upside: -77.60%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $524.05
Upside: -6.50%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $211.06
Upside: +144.01%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $207.51
Upside: +13.25%